Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC

Patients from Asia with non-small-cell lung cancer (NSCLC) often have mutations in the epidermal growth factor receptor (EGFR) gene. While an increasing number of EGFR tyrosine kinase inhibitors (TKIs) are now available for patients with EGFR mutation-positive NSCLC, most patients inevitably develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Rong, Zhou, Jianying, Ling, Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234848/
https://www.ncbi.nlm.nih.gov/pubmed/35770234
http://dx.doi.org/10.1177/11795549221103215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234848/
https://www.ncbi.nlm.nih.gov/pubmed/35770234
http://dx.doi.org/10.1177/11795549221103215

Ejemplares similares